Add to ORKGSorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepatocellular carcinoma. Dermatologic side effects include hand-foot skin reaction, facial and scalp erythema and desquamation, splinter subungual hemorrhages, alopecia, pruritus, xerosis, keratoacanthomas, and squamous cell carcinomas. We report sudden eruption of melanocytic nevi diffusely in a patient receiving sorafenib
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable ...
Background:We report two cases in which severe skin disorders developed during sorafenib treatment i...
The term, acquired perforating dermatoses (APD), represents a group of skin conditions that develop ...
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepat...
Sorafenib (NexavarⓇ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has re...
Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepa...
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanc...
Sorafenib (BAY 43-9006, Nexavar®) is a new biaryl urea that shows anti-mytotic and anti-angiogenetic...
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its re...
Objective: Sorafenib is one of the few standard agents for metastatic renal cell carcinoma. Although...
Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma. As with si...
ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carci...
Abstract Background Sorafenib is an oral multikinase inhibitor that targets Raf serine/threonine rec...
Sorafenib is a novel small molecule multiple kinase inhibitor which has been used for metastatic ren...
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell ...
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable ...
Background:We report two cases in which severe skin disorders developed during sorafenib treatment i...
The term, acquired perforating dermatoses (APD), represents a group of skin conditions that develop ...
Sorafenib is a multikinase inhibitor FDA-approved for the treatment of advanced renal cell and hepat...
Sorafenib (NexavarⓇ, BAY 43-9006) is a novel, orally administered multi-kinase inhibitor that has re...
Sorafenib is a multikinase inhibitor commonly used for the treatment of advanced renal cell and hepa...
Sorafenib is a tyrosine kinase inhibitor approved for the treatment of primary kidney cancer, advanc...
Sorafenib (BAY 43-9006, Nexavar®) is a new biaryl urea that shows anti-mytotic and anti-angiogenetic...
Sorafenib is a multikinase inhibitor thought to target vascular endothelial growth factor and its re...
Objective: Sorafenib is one of the few standard agents for metastatic renal cell carcinoma. Although...
Sorafenib is an oral multikinase inhibitor used in the treatment of renal cell carcinoma. As with si...
ABSTRACTSorafenib an oral tyrosine kinase inhibitor is used in the treatment of hepatocellular carci...
Abstract Background Sorafenib is an oral multikinase inhibitor that targets Raf serine/threonine rec...
Sorafenib is a novel small molecule multiple kinase inhibitor which has been used for metastatic ren...
Background: Sorafenib is a new therapeutic agent being used in hepatocellular carcinoma, renal cell ...
Sorafenib, a tyrosine kinase inhibitor, is approved for the treatment of patients with unresectable ...
Background:We report two cases in which severe skin disorders developed during sorafenib treatment i...
The term, acquired perforating dermatoses (APD), represents a group of skin conditions that develop ...